582
Background:
Timely, comprehensive biomarker testing is essential to identify actionable genomic alterations and guide targeted therapy in patients with advanced solid tumors. However, community and academic cancer centers often encounter delays in ordering, prolonged turnaround from diagnosis to results, an...
Amany R. Keruakous, W. Waugh, Samuel K. Caughron et al.· JCO Oncology Practice· 0 citations
PURPOSE
Preclinical data suggest that the anti-cancer efficacy of ATR inhibitors can be synergistically enhanced by low-dose gemcitabine. To test the clinical feasibility of this regimen, we conducted a phase 1 trial of low-dose gemcitabine combined with the ATR inhibitor elimusertib (BAY1895344).
PATIENTS AND METHOD...
T. Jayakrishnan, Rebecca L. Porter, Alice P. Chen et al.· Cancer Research Communicatio...· 0 citations
The combination of azenosertib and gemcitabine was associated with substantial myelosuppression in patients with metastatic PDAC previously treated with FOLFIRINOX, limiting further clinical evaluation of this dosing strategy.
B. Huffman, Haeseong Park, N. Jackson et al.· Cancer Research· 0 citations
These findings establish RAS-pathway focused combinatorial CRISPR screening as a robust approach for identifying clinically actionable combination vulnerabilities and nominate FGFR signaling as a lineage-specific mediator of KRAS inhibitor resistance in PDAC.
R. Ebright, Yao He, Alan Zhang et al.· Cancer Research· 0 citations
Oncogenic KRAS drives >90% of pancreatic ductal adenocarcinoma (PDAC), and the pan-RAS inhibitor daraxonrasib doubles overall survival, but adaptive and acquired resistance limit the depth and duration of responses. To systematically map combination vulnerabilities, we developed RAS+, a digenic CRISPR knockout library...
R. Ebright, Yao He, Alan Zhang et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.